Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Skin cancer

Risk of melanoma in men taking erectile dysfunction drugs driven by sun exposure

Study of men taking phosphodiesterase 5 inhibitors found an increased risk of melanoma driven by sun exposure.

Men who use phosphodiesterase 5 (PDE5) inhibitors for erectile dysfunction are feared to be at higher risk of melanoma, but it is unclear whether this is causal or related to sun exposure.

To investigate, researchers from the London School of Hygiene and Tropical Medicine used national data to compare 145,104 men prescribed PDE5 inhibitors with 560,933 unexposed men.

They found a weak association between PDE5 use and malignant melanoma (hazard ratio 1.14, 95% confidence interval 1.01–1.29; P=0.04). However, there was a similar increase in risk for basal cell carcinoma and solar keratosis, linked strongly to sun exposure. Solar keratosis was also associated with subsequent PDE5 inhibitor use.

In PLoS Medicine (online, 14 June 2016)[1], the researchers say the results strongly suggest that the risk of melanoma is driven by increased sun exposure among men who use PDE5 inhibitors.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2016.20201315

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £535.00Buy now
  • Lecture Notes in Pharmacy Practice

    Lecture Notes in Pharmacy Practice

    A comprehensive study guide which summarises the basic principles in pharmacy practice. Clear, bulleted information for quick reference.

    £43.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Close up of a melanoma

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.